NO309238B1 - Fremstilling av proteiner ved bruk av homolog rekombinasjon - Google Patents
Fremstilling av proteiner ved bruk av homolog rekombinasjon Download PDFInfo
- Publication number
- NO309238B1 NO309238B1 NO912642A NO912642A NO309238B1 NO 309238 B1 NO309238 B1 NO 309238B1 NO 912642 A NO912642 A NO 912642A NO 912642 A NO912642 A NO 912642A NO 309238 B1 NO309238 B1 NO 309238B1
- Authority
- NO
- Norway
- Prior art keywords
- gene
- cells
- amplifiable
- region
- host cells
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 141
- 102000004169 proteins and genes Human genes 0.000 title claims description 30
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 238000002744 homologous recombination Methods 0.000 title abstract description 25
- 230000006801 homologous recombination Effects 0.000 title abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 37
- 210000004027 cell Anatomy 0.000 claims description 99
- 108020004414 DNA Proteins 0.000 claims description 46
- 239000012634 fragment Substances 0.000 claims description 35
- 230000003321 amplification Effects 0.000 claims description 19
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 19
- 239000003550 marker Substances 0.000 claims description 15
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims description 12
- 108020001096 dihydrofolate reductase Proteins 0.000 claims description 12
- 101150074155 DHFR gene Proteins 0.000 claims description 9
- 238000002955 isolation Methods 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 7
- 238000010276 construction Methods 0.000 claims description 7
- 210000005260 human cell Anatomy 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 210000000349 chromosome Anatomy 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 230000009466 transformation Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 230000031864 metaphase Effects 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 239000003139 biocide Substances 0.000 claims description 3
- 239000000090 biomarker Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 10
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 17
- 239000013612 plasmid Substances 0.000 description 15
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 13
- 102100031939 Erythropoietin Human genes 0.000 description 13
- 239000013598 vector Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 238000004520 electroporation Methods 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 230000000644 propagated effect Effects 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000006152 selective media Substances 0.000 description 5
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 108090000157 Metallothionein Proteins 0.000 description 3
- 241001045988 Neogene Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 101150091879 neo gene Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101150003725 TK gene Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 102000047823 human PLAT Human genes 0.000 description 2
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
- 229940097277 hygromycin b Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001455 anti-clotting effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 101150106093 gpt gene Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/206—Pseudochromosomes, minichrosomosomes of yeast origin, e.g. YAC, 2u
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43206989A | 1989-11-06 | 1989-11-06 | |
PCT/US1990/006436 WO1991006667A1 (en) | 1989-11-06 | 1990-11-06 | Production of proteins using homologous recombination |
Publications (3)
Publication Number | Publication Date |
---|---|
NO912642D0 NO912642D0 (no) | 1991-07-05 |
NO912642L NO912642L (no) | 1991-09-05 |
NO309238B1 true NO309238B1 (no) | 2001-01-02 |
Family
ID=23714629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO912642A NO309238B1 (no) | 1989-11-06 | 1991-07-05 | Fremstilling av proteiner ved bruk av homolog rekombinasjon |
Country Status (14)
Country | Link |
---|---|
US (3) | US5578461A (de) |
EP (3) | EP0945515A3 (de) |
JP (2) | JPH04505104A (de) |
KR (1) | KR100233781B1 (de) |
AT (2) | ATE174058T1 (de) |
AU (1) | AU635844B2 (de) |
CA (1) | CA2045175C (de) |
DE (2) | DE69032809T2 (de) |
DK (2) | DK0747485T3 (de) |
ES (2) | ES2090297T5 (de) |
GR (2) | GR3021105T3 (de) |
NO (1) | NO309238B1 (de) |
SG (2) | SG122763A1 (de) |
WO (2) | WO1991006667A1 (de) |
Families Citing this family (254)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048729A (en) | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
ATE174058T1 (de) * | 1989-11-06 | 1998-12-15 | Cell Genesys Inc | Herstellung von proteinen mittels homologer rekombination |
US5272071A (en) * | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
ATE156189T1 (de) * | 1989-12-22 | 1997-08-15 | Applied Research Systems | Modifikation der endogenen genexpression mit hilfe eines regulatorischen elements mittels homologe rekombination |
GB9028062D0 (en) * | 1990-12-24 | 1991-02-13 | Agricultural & Food Res | Production of transgenic animals |
WO1992019255A1 (en) * | 1991-05-06 | 1992-11-12 | Cell Genesys, Inc. | Gene manipulation and expression using genomic elements |
ES2214474T3 (es) * | 1991-05-31 | 2004-09-16 | Genentech, Inc. | Aumento de la expresion mediante orientacion genica en secuencias endogenas de tipo retrovirus. |
AU2515992A (en) * | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US6063630A (en) * | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
US6054288A (en) * | 1991-11-05 | 2000-04-25 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US5641670A (en) * | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US6692737B1 (en) | 1991-11-05 | 2004-02-17 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
NZ245015A (en) * | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
US5968502A (en) * | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US20020108136A1 (en) * | 1997-03-21 | 2002-08-08 | Sri | Transgenic animals produced by homologous sequence targeting |
AU4401993A (en) * | 1992-06-04 | 1993-12-30 | Exemplar Corporation | Insertion of heterologous dna outside of known chromosomal genes |
US6670178B1 (en) | 1992-07-10 | 2003-12-30 | Transkaryotic Therapies, Inc. | In Vivo production and delivery of insulinotropin for gene therapy |
US6531124B1 (en) | 1992-07-10 | 2003-03-11 | Transkaryotic Therapies, Inc. | In vivo production and delivery of insulinotropin for gene therapy |
US5733753A (en) * | 1992-12-22 | 1998-03-31 | Novo Nordisk A/S | Amplification of genomic DNA by site specific integration of a selectable marker construct |
CA2161088A1 (en) | 1993-04-21 | 1994-10-27 | Austin Gerard Smith | Expression of heterologous genes according to a targeted expression profile |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
US6001968A (en) * | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6124448A (en) * | 1994-08-17 | 2000-09-26 | The Rockfeller University | Nucleic acid primers and probes for the mammalian OB gene |
US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
US6471956B1 (en) | 1994-08-17 | 2002-10-29 | The Rockefeller University | Ob polypeptides, modified forms and compositions thereto |
US6124439A (en) * | 1994-08-17 | 2000-09-26 | The Rockefeller University | OB polypeptide antibodies and method of making |
US5759775A (en) | 1994-10-27 | 1998-06-02 | Genetech, Inc. | Methods for detecting nucleic acids encoding AL--1 neurotrophic factor |
US6610296B2 (en) | 1995-10-26 | 2003-08-26 | Genentech, Inc. | Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin |
ATE449849T1 (de) | 1996-01-08 | 2009-12-15 | Genentech Inc | Ob rezeptor-variante und liganden |
US7084252B1 (en) | 1996-01-16 | 2006-08-01 | The Rockefeller University | DB, the receptor for leptin |
US7148004B1 (en) | 1997-01-16 | 2006-12-12 | The Rockefeller University | Oligonucleotides of the OB-R isoforms and methods of diagnosing body weight |
US7063958B1 (en) | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
US7619079B2 (en) | 1996-02-14 | 2009-11-17 | The Rockefeller University | Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof |
US5792210A (en) * | 1996-06-10 | 1998-08-11 | Environmental Behavior Modification Inc. | Electrical tongue stimulator and method for addiction treatment |
JP2000517185A (ja) | 1996-08-29 | 2000-12-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 新規なメタロプロテアーゼファミリーkuz |
US6566089B1 (en) * | 1996-09-04 | 2003-05-20 | Tularik Inc. | Cell-based drug screens for regulators of gene expression |
AU4424597A (en) * | 1996-09-13 | 1998-04-02 | Novo Nordisk Biotech, Inc. | Cells having dna insertion mutations which produce altered amounts of a polypeptide |
JPH10117771A (ja) * | 1996-10-23 | 1998-05-12 | Natl Food Res Inst | 冷凍生地耐性実用パン酵母 |
US5925544A (en) * | 1996-11-18 | 1999-07-20 | Novo Nordisk A/S | Method of homologous recombination followed by in vivo selection of DNA amplification |
US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
DE69835360T2 (de) | 1997-01-17 | 2007-08-16 | Maxygen, Inc., Redwood City | EVOLUTION Prokaryotischer GANZER ZELLEN DURCH REKURSIVE SEQUENZREKOMBINATION |
US7148054B2 (en) * | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
US6777196B2 (en) | 1997-02-18 | 2004-08-17 | Genentech, Inc. | Neurturin receptor |
US6372453B1 (en) | 1997-02-18 | 2002-04-16 | Genetech, Inc. | Neurturin receptor |
US6025157A (en) * | 1997-02-18 | 2000-02-15 | Genentech, Inc. | Neurturin receptor |
PT981637E (pt) | 1997-03-14 | 2005-09-30 | Biogen Idec Inc | Metodo para integrar genes em sitios especificos em celulas de mamifero atraves de recombinacao homologa e vectores para a realizacao do mesmo |
US5948653A (en) * | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
US6172211B1 (en) | 1997-07-11 | 2001-01-09 | Boehringer Ingelheim International Gmbh | Nucleic acid encoding tag7 polypeptide |
DK0986644T3 (da) * | 1997-07-23 | 2007-01-29 | Roche Diagnostics Gmbh | Fremstilling af erythropoietin ved endogen genaktivering med virale promotorer |
US6391633B1 (en) | 1997-07-23 | 2002-05-21 | Roche Diagnostics Gmbh | Production of erythropoietin by endogenous gene activation |
EP1000154B1 (de) * | 1997-07-23 | 2007-02-21 | Roche Diagnostics GmbH | Identifizierung humaner zellinien zur produktion humaner proteine durch endogene genaktivierung |
PT1000154E (pt) | 1997-07-23 | 2007-03-30 | Roche Diagnostics Gmbh | Identificação de linhas celulares humanas para a produção de proteínas humanas por activação endógena de genes |
US6548296B1 (en) | 1997-07-23 | 2003-04-15 | Roche Diagnostics Gmbh | Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof |
CA2304642C (en) | 1997-09-26 | 2014-11-18 | Athersys, Inc. | Expression of endogenous genes by non-homologous recombination of a vector construct with cellular dna |
US7316923B1 (en) | 1997-09-26 | 2008-01-08 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
US6897066B1 (en) | 1997-09-26 | 2005-05-24 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
ZA989497B (en) † | 1997-10-20 | 2000-04-19 | Roche Diagnostics Gmbh | Positive-negative selection in homologous recombination. |
KR100760221B1 (ko) | 1997-11-28 | 2007-10-30 | 세로노 제네틱스 인스티튜트 에스.에이. | 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도 |
AU757930B2 (en) | 1997-12-01 | 2003-03-13 | Roche Diagnostics Gmbh | Optimization of cells for endogenous gene activation |
JPH11243944A (ja) * | 1998-03-04 | 1999-09-14 | Natl Food Res Inst | 製パン用乾燥耐性実用パン酵母 |
US6294655B1 (en) | 1998-04-03 | 2001-09-25 | Hyseq, Inc. | Anti-interleukin-1 receptor antagonist antibodies and uses thereof |
US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
US6541623B1 (en) | 1998-04-03 | 2003-04-01 | Hyseq, Inc. | Interleukin—1 receptor antagonist and uses thereof |
US6426191B1 (en) | 1998-04-03 | 2002-07-30 | Hyseq, Inc. | Assays involving an IL-1 receptor antagonist |
EP1098986B1 (de) | 1998-07-21 | 2011-12-28 | Millipore Corporation | Ein ein allgegenwärtiges chromatin-öffnendes element (ucoe) enthaltendes polynucleotid |
JP4486256B2 (ja) * | 1998-10-22 | 2010-06-23 | ザ・ジェネラル・ホスピタル・コーポレイション | 副甲状腺ホルモン(PTH)および副甲状腺ホルモン関連ペプチド(PTHrP)の生物活性ペプチドおよびペプチド誘導体 |
US6773911B1 (en) | 1998-11-23 | 2004-08-10 | Amgen Canada Inc. | Apoptosis-inducing factor |
TW570977B (en) * | 1998-12-07 | 2004-01-11 | Li-Wei Hsu | An expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof |
DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
ES2321568T3 (es) | 1999-05-18 | 2009-06-08 | Dyax Corp. | Bibliotecas de fragmentos fab y procedimientos para su uso. |
US6495360B1 (en) * | 1999-05-28 | 2002-12-17 | Photogen, Inc. | Method for enhanced protein stabilization and for production of cell lines useful for production of such stabilized proteins |
US20050129669A1 (en) * | 1999-06-21 | 2005-06-16 | Transkaryotic Therapies, Inc., A Massachusetts Corporation | DNA construct for effecting homologous recombination and uses thereof |
US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
ATE412670T1 (de) | 1999-09-29 | 2008-11-15 | Gen Hospital Corp | Parathyroid hormon (pth) polypeptidderivate |
AU7734800A (en) * | 1999-09-29 | 2001-04-30 | General Hospital Corporation, The | Polypeptide derivatives of parathyroid hormone (pth) |
AU1647501A (en) | 1999-12-10 | 2001-06-18 | Cytos Biotechnology Ag | Replicon based activation of endogenous genes |
AU2001234443A1 (en) * | 2000-01-13 | 2001-07-24 | Novozymes Biotech, Inc. | Methods for producing a polypeptide using a crippled translational initiator sequence |
AU2001243345A1 (en) | 2000-02-29 | 2001-09-12 | Millennium Pharmaceuticals, Inc. | 1983, 52881, 2398, 45449, 50289, and 52872, g protein-coupled receptors and uses therefor |
EP1714661A3 (de) | 2000-05-19 | 2012-03-14 | The Center for Blood Research, INC. | Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität |
US6686188B2 (en) | 2000-05-26 | 2004-02-03 | Amersham Plc | Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle |
US6656700B2 (en) | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
GB0018876D0 (en) * | 2000-08-01 | 2000-09-20 | Applied Research Systems | Method of producing polypeptides |
WO2002012437A2 (en) * | 2000-08-03 | 2002-02-14 | Schooten Wim Van | Production of humanized antibodies in transgenic animals |
JP2003000268A (ja) | 2000-08-25 | 2003-01-07 | Pfizer Prod Inc | 血管新生にかかわる疾患を診断および治療するための方法および組成物 |
ES2522890T3 (es) | 2000-12-06 | 2014-11-19 | Anthrogenesis Corporation | Método para recolectar células troncales placentarias |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
US20030032179A1 (en) | 2000-12-06 | 2003-02-13 | Hariri Robert J. | Post-partum mammalian placenta, its use and placental stem cells therefrom |
ATE505204T1 (de) | 2000-12-20 | 2011-04-15 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
MXPA03005406A (es) * | 2000-12-20 | 2003-09-25 | Hoffmann La Roche | Conjugados de eritropoyetina. |
PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
KR101132545B1 (ko) | 2001-02-14 | 2012-04-02 | 안트로제네시스 코포레이션 | 산후 포유류의 태반, 이의 용도 및 태반 줄기세포 |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
EP2184359B1 (de) | 2001-06-06 | 2016-03-02 | Bioriginal Food & Science Corp. | Samen-spezifische Promotoren aus Flachs (Linum usitatissimum L.) |
EP1925671A1 (de) | 2001-06-06 | 2008-05-28 | Bioriginal Food & Science Corp. | Flax-(Linum usitatissimum L.)-Samenspezifische Promotoren |
US7572765B2 (en) * | 2001-07-23 | 2009-08-11 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (PTH) analogs |
JP2005511500A (ja) | 2001-08-31 | 2005-04-28 | ザ ロックフェラー ユニバーシティー | 脳におけるホスホジエステラーゼ活性およびホスホジエステラーゼ1b媒介シグナル伝達の調節 |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
EP1455815A4 (de) | 2001-12-19 | 2006-11-02 | Millennium Pharm Inc | Mitglieder der familie der humanen diacylglycerol-acyltransferase 2 (dgat2) und ihre verwendung |
WO2003054172A2 (en) * | 2002-01-17 | 2003-07-03 | Lonza Biologics Plc. | Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium |
NZ579705A (en) | 2002-02-13 | 2011-07-29 | Anthrogenesis Corp | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
WO2003094841A2 (en) * | 2002-05-06 | 2003-11-20 | Functional Genetics, Inc. | Mammalian genes involed in rapamycin resistance and tumorgenesis: annexin xiii genes |
AU2003239589A1 (en) | 2002-05-24 | 2003-12-12 | Schering-Plough Ltd. | Eta-1 gene and methods for use |
AU2003265525A1 (en) * | 2002-08-15 | 2004-03-19 | Functional Genetics, Inc. | Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr7 genes |
AU2003268135A1 (en) * | 2002-08-15 | 2004-03-19 | Functional Genetics, Inc. | Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr6 genes |
US7459435B2 (en) | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
AU2003293013A1 (en) | 2002-11-21 | 2004-06-18 | University Of Massachusets | Diagnosing and treating hematopoietic cancers |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
EP2112229A3 (de) | 2002-11-25 | 2009-12-02 | Sequenom, Inc. | Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen |
KR101042448B1 (ko) | 2002-11-26 | 2011-06-16 | 안트로제네시스 코포레이션 | 세포요법제, 세포요법제 단위 및 이를 이용한 치료방법 |
US20050048041A1 (en) * | 2003-01-13 | 2005-03-03 | Rao Mahendra S. | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
CA2513226A1 (en) * | 2003-01-13 | 2004-07-29 | Mahendra S. Rao | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
ES2565327T3 (es) | 2003-01-14 | 2016-04-04 | Dana Farber Cancer Institute | Sensibilizador de terapia del cáncer |
US8021833B2 (en) | 2003-02-12 | 2011-09-20 | Functional Genetics, Inc. | Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions |
AU2003220380A1 (en) * | 2003-03-19 | 2004-11-19 | Bristol-Myers Squibb Company | CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS |
JP4871128B2 (ja) | 2003-07-17 | 2012-02-08 | ザ ジェネラル ホスピタル コーポレイション | 高次構造的に制約された副甲状腺ホルモン(pth)アナログ |
US7287952B2 (en) * | 2003-07-23 | 2007-10-30 | Lockheed Martin Corporation | Feeder load automation system and method of use |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US11311574B2 (en) | 2003-08-08 | 2022-04-26 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
CN1897959A (zh) | 2003-09-29 | 2007-01-17 | 沃伦药品公司 | 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子 |
EP1694706B1 (de) | 2003-11-01 | 2012-04-04 | Merck Patent GmbH | Modifizierter anti-cd52-antikörper |
DK1696947T3 (en) * | 2003-12-19 | 2014-03-17 | Hoffmann La Roche | APPLICATION OF ERYTHROPOIETIN IN THE TREATMENT OF DISORDERS OF THE IRON DISTRIBUTION IN CHRONIC INFLAMMATORY INTESTINAL DISEASES |
DK1709161T3 (da) * | 2004-01-19 | 2009-01-26 | Nsgene As | Humane terapeutiske celler, som udskiller nervevækstfaktor |
WO2006017621A2 (en) | 2004-08-02 | 2006-02-16 | Janssen Pharmaceutica N.V. | IRAK1c SPLICE VARIANT AND ITS USE |
US7893197B2 (en) | 2004-08-25 | 2011-02-22 | Janssen Pharmaceutica N.V. | Relaxin-3 chimeric polypeptides and their preparation and use |
EP2338993B1 (de) | 2004-09-02 | 2013-06-12 | Yale University | Regulierung von Onkogenen durch mikro-RNAs |
CN101389214A (zh) | 2004-10-22 | 2009-03-18 | 雷维维科公司 | 具有基因修饰免疫系统的有蹄类动物 |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
CA2595676A1 (en) * | 2005-01-25 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
EP2365086A1 (de) | 2005-02-09 | 2011-09-14 | Bioriginal Food & Science Corporation | Neuartige Omega-3-Fettsäure-Desaturase-Familienmitglieder und Verwendungen davon |
DK1874282T3 (da) | 2005-04-06 | 2010-10-25 | Adamas Pharmaceuticals Inc | Fremgangsmåder og præparater til behandling af CNS lidelser |
US8354384B2 (en) | 2005-06-23 | 2013-01-15 | Yale University | Anti-aging micrornas |
EP2530146A1 (de) | 2005-10-13 | 2012-12-05 | Anthrogenesis Corporation | Immunmodulation unter Verwendung von Plazenta-Stammzellen |
US7767420B2 (en) | 2005-11-03 | 2010-08-03 | Momenta Pharmaceuticals, Inc. | Heparan sulfate glycosaminoglycan lyase and uses thereof |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
CN103060263B (zh) | 2005-12-29 | 2016-03-16 | 人类起源公司 | 胎盘干细胞群 |
AU2006332679A1 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
DE102006004008A1 (de) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose |
SI2004683T1 (sl) | 2006-03-24 | 2016-09-30 | Biogen Hemophilia Inc. | Pc5 kot encim za obdelavo propeptida faktorja ix |
US10522240B2 (en) | 2006-05-03 | 2019-12-31 | Population Bio, Inc. | Evaluating genetic disorders |
US7702468B2 (en) | 2006-05-03 | 2010-04-20 | Population Diagnostics, Inc. | Evaluating genetic disorders |
EP2236623A1 (de) | 2006-06-05 | 2010-10-06 | Cancer Care Ontario | Feststellung des Risikos für Kolorektalkrebs |
ES2529234T3 (es) | 2006-08-04 | 2015-02-18 | Prolong Pharmaceuticals, LLC | Eritropoyetina modificada |
WO2008019062A2 (en) * | 2006-08-04 | 2008-02-14 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (pth) |
CN101506235B (zh) | 2006-09-01 | 2012-07-25 | 人类多细胞株治疗学公司 | 人或人源化免疫球蛋白在非人转基因动物中增强的表达 |
NZ606814A (en) | 2006-10-23 | 2014-10-31 | Anthrogenesis Corp | Methods and compositions for treatment of bone defects with placental cell populations |
EP2078075B1 (de) * | 2006-10-30 | 2015-09-02 | Eli Lilly and Company | Verbesserte antikörperproduktion durch rhgp (random homozygous gene pertubation) |
KR101569168B1 (ko) | 2007-02-12 | 2015-11-13 | 안트로제네시스 코포레이션 | 태반 줄기세포를 이용한 염증 질환의 치료 |
EP2079839A4 (de) | 2007-03-05 | 2009-11-18 | Cancer Care Ontario | Abschätzung des kolorektalkarzinomrisikos |
EA200971050A1 (ru) | 2007-05-11 | 2010-06-30 | Томас Джефферсон Юниверсити | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений |
WO2008141176A1 (en) | 2007-05-11 | 2008-11-20 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
US8252897B2 (en) | 2007-06-21 | 2012-08-28 | Angelica Therapeutics, Inc. | Modified toxins |
AR067537A1 (es) | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Purificacion de polipeptidos pegilados |
AR067536A1 (es) | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea |
WO2009010107A1 (en) | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
CN104072606B (zh) | 2007-08-01 | 2017-09-22 | 总医院有限公司 | 利用g蛋白偶联受体和相关组合物的筛选方法 |
US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
CA2700643A1 (en) | 2007-09-24 | 2009-04-02 | Cornell University | Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon |
JP5795476B2 (ja) | 2007-09-28 | 2015-10-14 | アンスロジェネシス コーポレーション | ヒト胎盤灌流液およびヒト胎盤由来中間ナチュラルキラー細胞を使用した腫瘍抑制 |
US8501449B2 (en) | 2007-12-04 | 2013-08-06 | Proteon Therapeutics, Inc. | Recombinant elastase proteins and methods of manufacturing and use thereof |
US20100279423A1 (en) | 2008-01-02 | 2010-11-04 | Mark David Brennan | Genetic markers of mental illness |
EP2581459A3 (de) | 2008-01-17 | 2013-07-17 | Suregene LLC | Genetische Marker von Geisteskrankheiten |
JP2011515078A (ja) * | 2008-03-01 | 2011-05-19 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | SPARC特異的miRNAを使用する、治療、診断、及び拮抗物質発見方法 |
WO2009114185A2 (en) | 2008-03-12 | 2009-09-17 | The Rockefeller University | Methods and compositions for translational profiling and molecular phenotyping |
JP2011519951A (ja) * | 2008-05-07 | 2011-07-14 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | miRNAによる薬物治療の増強 |
DK2330889T3 (en) | 2008-08-20 | 2017-01-30 | Anthrogenesis Corp | Improved cell composition and process for making the same |
US8962247B2 (en) | 2008-09-16 | 2015-02-24 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses |
US8476013B2 (en) | 2008-09-16 | 2013-07-02 | Sequenom, Inc. | Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
EP2342361A4 (de) | 2008-09-25 | 2012-11-14 | Suregene Llc | Genetische marker zur risikobeurteilung der entwicklung einer manisch-depressiven erkrankung |
CA2738252C (en) | 2008-09-26 | 2018-05-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
WO2010037224A1 (en) | 2008-10-03 | 2010-04-08 | St. Michael's Hospital | Method for preventing and treating cardiovascular diseases with brca1 |
US20100120063A1 (en) * | 2008-10-10 | 2010-05-13 | Discoverx Corporation | GPCR Arrestin Assays |
EP2348827B1 (de) | 2008-10-27 | 2015-07-01 | Revivicor, Inc. | Immunsupprimierte huftiere |
ES2723098T3 (es) | 2008-11-04 | 2019-08-21 | Janssen Pharmaceutica Nv | Agonistas del péptido CRHR2 y usos de los mismos |
WO2010059828A1 (en) | 2008-11-19 | 2010-05-27 | Anthrogenesis Corporation | Amnion derived adherent cells |
JP2012515532A (ja) | 2009-01-20 | 2012-07-12 | ラモット アット テル アビブ ユニバーシティ, リミテッド | Mir−21プロモーター駆動性標的がん治療 |
WO2010088522A2 (en) | 2009-01-30 | 2010-08-05 | Ab Biosciences, Inc. | Novel lowered affinity antibodies and uses therefor |
US8211655B2 (en) * | 2009-02-12 | 2012-07-03 | Discoverx Corporation | Wild-type receptor assays |
CN102711801A (zh) | 2009-11-04 | 2012-10-03 | 詹森药业有限公司 | 用顶压素样肽治疗心力衰竭的方法 |
US8968740B2 (en) | 2009-11-13 | 2015-03-03 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
EP3037435B1 (de) | 2009-11-17 | 2019-08-07 | MUSC Foundation for Research Development | Humane monoklonale antikörper gegen menschliches nukleolin |
ES2577017T3 (es) | 2009-12-22 | 2016-07-12 | Sequenom, Inc. | Procedimientos y kits para identificar la aneuploidia |
ES2646750T3 (es) | 2010-01-26 | 2017-12-15 | Anthrogenesis Corporation | Tratamiento de cánceres relacionados con hueso utilizando células madre placentarias |
CN102971342B (zh) | 2010-01-28 | 2016-08-03 | Ab生物科学公司 | 亲和力降低的新抗体和制备所述抗体的方法 |
US9631018B2 (en) | 2010-03-26 | 2017-04-25 | The Trustees Of Dartmouth College | Vista regulatory T cell mediator protein, vista binding agents and use thereof |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
NZ630009A (en) | 2010-04-07 | 2016-05-27 | Anthrogenesis Corp | Angiogenesis using placental stem cells |
BR112012028949B1 (pt) | 2010-05-13 | 2020-11-17 | Chugai Seiyaku Kabushiki Kaisha | polipeptídeo análogo do hormônio paratireoideo, seu uso e método de produção, bem como ácido nucleico, vetor de expressão, célula e composição farmacêutica |
EP2593542B1 (de) | 2010-07-13 | 2018-01-03 | Anthrogenesis Corporation | Verfahren zur erzeugung von natürlichen killerzellen |
WO2012018387A2 (en) | 2010-08-02 | 2012-02-09 | Population Diagnotics, Inc. | Compositions and methods for discovery of causative mutations in genetic disorders |
BR112013005890B1 (pt) | 2010-09-14 | 2022-02-08 | F Hoffmann-La Roche Ag | Método para purificar eritropoietina peguilada |
CA2819635A1 (en) | 2010-12-01 | 2012-06-07 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
EP2471543A1 (de) | 2010-12-02 | 2012-07-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Toleranzinduktion oder Immunsuppression zur Verhinderung von insbesondere Transplantat-Wirt-Reaktion (GvHD) durch kurzzeitige Vorinkubation von transplantierten Zellsuspensionen, Geweben oder Organen, die mit Liganden zu Zelloberflächenmolekülen beschichtet sind |
EP2658557A1 (de) | 2010-12-31 | 2013-11-06 | Anthrogenesis Corporation | Verbesserung der plazentastammzellenpotenz mit modulatorischen rna-molekülen |
AU2012262273B2 (en) | 2011-06-01 | 2017-09-14 | Celularity Inc. | Treatment of pain using placental stem cells |
WO2013003697A1 (en) | 2011-06-30 | 2013-01-03 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
EP2739734A1 (de) | 2011-08-03 | 2014-06-11 | The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System | Behandlung von fibrose mit mikrorna-19b |
CA2851388C (en) | 2011-10-10 | 2023-11-21 | The Hospital For Sick Children | Methods and compositions for screening and treating developmental disorders |
DK2773779T3 (da) | 2011-11-04 | 2020-11-23 | Population Bio Inc | Fremgangsmåder og sammensætninger til diagnosticering, prognose og forebyggelse af neurologiske tilstande |
WO2013120018A1 (en) | 2012-02-09 | 2013-08-15 | Population Diagnostics, Inc. | Methods and compositions for screening and treating developmental disorders |
PL2814842T3 (pl) | 2012-02-15 | 2018-12-31 | Novo Nordisk A/S | Przeciwciała wiążące białko 1 rozpoznające peptydoglikan |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
ES2640268T3 (es) | 2012-02-15 | 2017-11-02 | Novo Nordisk A/S | Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1) |
ES2930180T3 (es) | 2012-03-02 | 2022-12-07 | Sequenom Inc | Métodos para enriquecer ácido nucleico canceroso a partir de una muestra biológica |
US9494597B2 (en) | 2012-04-02 | 2016-11-15 | Ab Biosciences, Inc. | Human control antibodies and uses therefor |
US20130280222A1 (en) * | 2012-04-18 | 2013-10-24 | Board Of Regents Of The University Of Texas System | Non-disruptive gene targeting |
US9920361B2 (en) | 2012-05-21 | 2018-03-20 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
WO2014011928A1 (en) | 2012-07-13 | 2014-01-16 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
CA2884704C (en) | 2012-09-07 | 2023-04-04 | Randolph J. Noelle | Vista modulators for diagnosis and treatment of cancer |
DK2895621T3 (da) | 2012-09-14 | 2020-11-30 | Population Bio Inc | Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande |
CA2922005A1 (en) | 2012-09-27 | 2014-04-03 | Population Diagnostics, Inc. | Methods and compositions for screening and treating developmental disorders |
CN103864913A (zh) | 2012-12-18 | 2014-06-18 | 联亚生技开发股份有限公司 | 重组蛋白 |
CN115137753A (zh) | 2013-02-05 | 2022-10-04 | 细胞结构公司 | 来自胎盘的自然杀伤细胞 |
WO2014168711A1 (en) | 2013-03-13 | 2014-10-16 | Sequenom, Inc. | Primers for dna methylation analysis |
EP2968450A4 (de) | 2013-03-15 | 2016-10-26 | Angelica Therapeutics Inc | Modifizierte toxine |
WO2014138921A1 (en) | 2013-03-15 | 2014-09-18 | Apotex Inc. | Enhanced liquid formulation stability of erythropoietin alpha through purification processing |
US10294295B2 (en) | 2013-11-27 | 2019-05-21 | Inis Biotech Llc | Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
WO2015097536A2 (en) | 2013-12-24 | 2015-07-02 | Janssen Pharmaceutical Nv | Anti-vista antibodies and fragments |
EP3736344A1 (de) | 2014-03-13 | 2020-11-11 | Sequenom, Inc. | Verfahren und prozesse zur nichtinvasiven beurteilung genetischer variationen |
JP2017509328A (ja) | 2014-03-21 | 2017-04-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ヌクレアーゼを使用しないゲノム編集 |
MX2016016310A (es) | 2014-06-11 | 2017-10-20 | A Green Kathy | Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral. |
WO2016036403A1 (en) | 2014-09-05 | 2016-03-10 | Population Diagnostics Inc. | Methods and compositions for inhibiting and treating neurological conditions |
EP3194581A4 (de) | 2014-09-15 | 2018-04-25 | Children's Medical Center Corporation | Verfahren und zusammensetzungen zur erhöhung der somatischen zellkerntransfer(scnt)-effizienz durch entfernung der histon h3-lysin-trimethylierung |
EP3015475A1 (de) | 2014-10-31 | 2016-05-04 | Novartis AG | Säugetierzellen zur Expression von Cytomegalovirus-Antigenen |
WO2016090347A1 (en) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
EP3031822A1 (de) | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus-Antigene |
EP3048114A1 (de) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus-Antigene und Verwendungen davon |
US10632151B2 (en) | 2015-01-22 | 2020-04-28 | University Of Massachusetts | Cancer immunotherapy |
EP3047856A1 (de) | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv-antigene und ihre verwendungen |
CN107922497B (zh) | 2015-06-24 | 2022-04-12 | 詹森药业有限公司 | 抗vista抗体和片段 |
CN116920085A (zh) | 2016-02-12 | 2023-10-24 | 詹森药业有限公司 | 抗-vista(b7h5)抗体 |
JP7157981B2 (ja) | 2016-03-07 | 2022-10-21 | チャールストンファーマ, エルエルシー | 抗ヌクレオリン抗体 |
CN109789201B (zh) | 2016-04-15 | 2023-06-16 | 伊穆奈克斯特股份有限公司 | 抗人vista抗体及其用途 |
JP7177035B2 (ja) | 2016-07-15 | 2022-11-22 | エフ.ホフマン-ラ ロシュ アーゲー | Peg化エリスロポエチンを精製するための方法 |
WO2018144807A2 (en) * | 2017-02-02 | 2018-08-09 | Massachusetts Institute Of Technology | Engineered yeast as a method for bioremediation |
US10240205B2 (en) | 2017-02-03 | 2019-03-26 | Population Bio, Inc. | Methods for assessing risk of developing a viral disease using a genetic test |
CN111801120A (zh) | 2017-12-29 | 2020-10-20 | 豪夫迈·罗氏有限公司 | 用于提供聚乙二醇化蛋白质组合物的方法 |
US20200323993A1 (en) | 2017-12-29 | 2020-10-15 | Hoffmann-La Roche Inc. | Process for providing pegylated protein composition |
EP3731873B1 (de) | 2017-12-29 | 2022-01-26 | F. Hoffmann-La Roche AG | Verfahren zur bereitstellung monopegylierter proteine |
SI3625368T1 (sl) | 2018-08-08 | 2023-04-28 | Pml Screening, Llc | Postopki z genetskim testiranjem za oceno tveganja za razvoj progresivne multifokalne levkoencefalopatije, ki jo povzroča virus John Cunningham |
EP4004018A1 (de) | 2019-07-24 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Modifizierte humane cytomegalovirus-proteine |
WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
WO2024129459A1 (en) | 2022-12-16 | 2024-06-20 | University Of Rochester | Repairmen! of barrier dysfunction in esophagus |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH634437A5 (fr) | 1979-03-14 | 1983-01-31 | Tokyo Shibaura Electric Co | Resistance de decharge. |
US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4656134A (en) * | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
JPH0795954B2 (ja) * | 1982-11-30 | 1995-10-18 | アメリカ合衆国 | 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法 |
ATE52800T1 (de) * | 1983-01-13 | 1990-06-15 | Max Planck Gesellschaft | Verfahren zum einbringen von expressionsfaehigen genen in pflanzenzellgenome und hybride ti plasmidvektoren enthaltende agrobacterium-staemme verwendbar in diesem verfahren. |
US4740461A (en) * | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
EP0273085A1 (de) * | 1986-12-29 | 1988-07-06 | IntraCel Corporation | Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen |
US4950599A (en) * | 1987-01-29 | 1990-08-21 | Wolf Bertling | Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments |
ZA88319B (en) * | 1987-02-06 | 1988-08-12 | Lubrizol Enterprises, Inc. | Ocs enhancer |
EP0317509A3 (de) * | 1987-11-16 | 1990-01-31 | Ciba-Geigy Ag | Gezielter Einbau von Genen ins pflanzliche Genom |
GB8807683D0 (en) * | 1988-03-31 | 1988-05-05 | Ici Plc | Regulation of gene expression |
ATE129289T1 (de) * | 1988-12-08 | 1995-11-15 | Abbott Lab | Verfahren zur induzierbaren genexpression unter verwendung eines dhfr-gens. |
FR2646438B1 (fr) * | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
WO1990014092A1 (en) * | 1989-05-18 | 1990-11-29 | Cell Genesys, Inc. | Single-strand site-directed modification of mammalian genes in vivo |
NL8901931A (nl) * | 1989-07-26 | 1991-02-18 | Mogen International N V En Rij | Werkwijze voor het plaatsgericht introduceren van vreemd dna in het genoom van planten. |
ATE174058T1 (de) * | 1989-11-06 | 1998-12-15 | Cell Genesys Inc | Herstellung von proteinen mittels homologer rekombination |
US5272071A (en) * | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
ATE156189T1 (de) * | 1989-12-22 | 1997-08-15 | Applied Research Systems | Modifikation der endogenen genexpression mit hilfe eines regulatorischen elements mittels homologe rekombination |
NZ245015A (en) * | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
-
1990
- 1990-11-06 AT AT95119039T patent/ATE174058T1/de not_active IP Right Cessation
- 1990-11-06 SG SG200205236A patent/SG122763A1/en unknown
- 1990-11-06 DE DE69032809T patent/DE69032809T2/de not_active Revoked
- 1990-11-06 CA CA002045175A patent/CA2045175C/en not_active Expired - Lifetime
- 1990-11-06 JP JP3500807A patent/JPH04505104A/ja active Pending
- 1990-11-06 ES ES91900640T patent/ES2090297T5/es not_active Expired - Lifetime
- 1990-11-06 DK DK95119039T patent/DK0747485T3/da active
- 1990-11-06 AU AU77407/91A patent/AU635844B2/en not_active Ceased
- 1990-11-06 EP EP98115060A patent/EP0945515A3/de not_active Withdrawn
- 1990-11-06 DE DE69027526T patent/DE69027526T3/de not_active Expired - Fee Related
- 1990-11-06 WO PCT/US1990/006436 patent/WO1991006667A1/en active IP Right Grant
- 1990-11-06 WO PCT/US1990/006425 patent/WO1991006666A1/en unknown
- 1990-11-06 SG SG9604355A patent/SG88714A1/en unknown
- 1990-11-06 EP EP95119039A patent/EP0747485B1/de not_active Revoked
- 1990-11-06 AT AT91900640T patent/ATE139574T1/de not_active IP Right Cessation
- 1990-11-06 KR KR1019910700717A patent/KR100233781B1/ko not_active IP Right Cessation
- 1990-11-06 EP EP91900640A patent/EP0452484B2/de not_active Expired - Lifetime
- 1990-11-06 DK DK91900640.3T patent/DK0452484T3/da active
- 1990-11-06 ES ES95119039T patent/ES2127458T3/es not_active Expired - Lifetime
-
1991
- 1991-07-05 NO NO912642A patent/NO309238B1/no unknown
-
1993
- 1993-08-05 US US08/102,567 patent/US5578461A/en not_active Expired - Lifetime
-
1995
- 1995-06-05 US US08/462,947 patent/US6015708A/en not_active Expired - Fee Related
- 1995-06-06 US US08/467,244 patent/US5981214A/en not_active Expired - Lifetime
-
1996
- 1996-09-19 GR GR960402466T patent/GR3021105T3/el unknown
-
1999
- 1999-02-10 GR GR990400414T patent/GR3029328T3/el unknown
-
2000
- 2000-12-06 JP JP2000371763A patent/JP2001186897A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO309238B1 (no) | Fremstilling av proteiner ved bruk av homolog rekombinasjon | |
US7235360B2 (en) | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same | |
US5830698A (en) | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same | |
EP0491875B1 (de) | Rekombinante dna-methode und vektoren, die dafür benutzt werden | |
EP2278021A2 (de) | Expressionsvektoren, Transfektionssysteme und Verfahren zu deren Verwendung | |
EP3680337A1 (de) | Säuger-expressionsvektor | |
KR100259933B1 (ko) | 게놈 엘리먼트를 이용한 유전자 조작 및 발현방법 | |
JP3582965B2 (ja) | 哺乳動物細胞用発現ベクター | |
US5747308A (en) | Recombinant DNA method | |
CN110982790B (zh) | 一种用于蛋白展示和表达的细胞株及其制备方法和应用 | |
US20040265860A1 (en) | Production of proteins using homologous recombination | |
NO891485L (no) | Fremgangsmaate til fremstilling av 22 kd sgh-protein og lineaer genevektor. | |
KR20050084867A (ko) | 페리틴 중쇄 유전자 로커스에 기초한 고발현 로커스 벡터 |